About: Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
Creator	Andonov, Anton Drebot, Michael Li, Yan Berry, Jody Andonova, Maya Gren, Jason Kitching, Paul Marszal, Peter Fernando, Lisa Weingartl, Hana Kabani, Amin Jones, Steven Nicolas, Brigitte Plummer, Frank Ranada, Francesca Sabara, Marta Yuan, Y Blake Ball, T Gubbins, Michael
Source	Elsevier; Medline; PMC
abstract	There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of 103 mAbs to the SARS virus. Subsequent screening steps reduced this panel to seventeen IgG mAbs. A single mAb, F26G15, is specific for the nucleoprotein as seen in Western immunoblot while five other mAbs react with the Spike protein. Two of these Spike-specific mAbs demonstrate the ability to neutralise SARS-CoV in vitro while another four Western immunoblot-negative mAbs also neutralise the virus. The utility of these mAbs for diagnostic development is demonstrated. Antibody from convalescent SARS patients, but not normal human serum, is also shown to specifically compete off binding of mAbs to whole SARS-CoV. These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development.
has issue date	2004-09-01(xsd:dateTime)
bibo:doi	10.1016/j.jviromet.2004.04.009
bibo:pmid	15234813
has license	no-cc
sha1sum (hex)	dadc371023bcc9e2150f5f5d47d7011a0ce4c918
schema:url	https://doi.org/10.1016/j.jviromet.2004.04.009
resource representing a document's title	Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
has PubMed Central identifier	PMC7119589
has PubMed identifier	15234813
schema:publication	J Virol Methods
resource representing a document's body	covid:dadc371023bcc9e2150f5f5d47d7011a0ce4c918#body_text
is schema:about of	named entity 'These' named entity 'Antibody' named entity 'convalescent' named entity 'human' named entity 'Spike' named entity 'These' named entity 'binding' named entity 'HIGHLY' named entity 'SARS VIRUS' named entity 'PURIFIED' named entity 'IN VITRO' named entity 'UTILITY' named entity 'BUT' named entity 'PATHOGENESIS' named entity 'SUBSEQUENT' named entity 'SPECIFIC' named entity 'PANEL' named entity 'SPECIFICITY' named entity 'MONOCLONAL ANTIBODY' named entity 'NEGATIVE' named entity 'SPIKE' named entity 'REQUIREMENTS' named entity 'DIAGNOSTIC TESTS' named entity 'IGG' named entity 'SINGLE' named entity 'REACT' named entity 'NEEDED' named entity 'ELISA' named entity 'DEVELOPMENT' named entity 'VIRUS' named entity 'CONVALESCENT' named entity 'ANTIGENS' named entity 'CORONAVIRUS' named entity 'SELECTION' named entity 'GLOBAL' named entity 'HUMAN SERUM' named entity 'NUCLEOPROTEIN' named entity 'SARS-COV' named entity 'PATIENTS' named entity 'SARS' named entity 'DEVELOPMENT' named entity 'REPORT' named entity '103' named entity 'EXPRESSED' named entity 'ANTIGEN' named entity 'PRESENTED' named entity 'MAB' named entity 'REDUCED' named entity 'COATING' named entity 'THEIR' named entity 'MONOCLONAL ANTIBODIES' named entity 'REAGENTS' named entity 'BASED' named entity 'BINDING' named entity 'STEPS' named entity 'SEVENTEEN' named entity 'INITIAL' named entity 'ANTIBODY' named entity 'SARS' named entity 'BIOLOGICAL ACTIVITY' named entity 'NEED' named entity 'WESTERN IMMUNOBLOT' named entity 'SPIKE PROTEIN'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software